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Summary
Background.  —  Improvements  in  the  treatment  of  children  with  congenital  heart  disease  have
led to  most  of  these  patients  reaching  adulthood.  Despite  the  increase  in  lifespan,  very  little  is
known about  their  quality  of  life  —  in  particular,  their  ability  to  obtain  a  mortgage  or  consumer
loan.
Aim. —  To  investigate  the  outcome  of  mortgage  and  loan  applications  made  by  adults  with
differential  severities  of  congenital  heart  disease.
Methods.  —  Four  hundred  and  seventy-six  patients  were  invited  to  participate  in  a
questionnaire-based  interview  by  phone.  Of  these  patients,  one  hundred  and  forty-two
responded.  Respondents  were  classiﬁed  into  three  categories  (‘signiﬁcant’,  ‘complex’  and
‘mild’) based  on  congenital  heart  disease  severity  according  to  the  Bethesda  conference.
Results. —  Ninety  patients  (64%)  had  applied  for  loans;  17  (16.5%)  did  not  report  their  heart
disease to  the  insurance  company,  13  were  refused  insurance  and  39  were  asked  to  pay  surplus
fees. The  imposed  fees  concerned  patients  classiﬁed  in  the  ‘signiﬁcant’  and  ‘complex’  groups
(P <  0.0001  and  P  <  0.003,  respectively,  compared  with  those  classiﬁed  in  the  ‘mild’  group).  Age,
sex, other  diseases,  cardiovascular  risk  factors  and  duration  of  the  loan  had  no  inﬂuence  on
loan application  outcomes.
Abbreviations: AERAS, s’Assurer et Emprunter avec un Risque Aggravé de Santé; CHD, congenital heart disease; INSEE,
Institut national de la statistique et des études économiques (National Institute of Statistics and Economic Studies).
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Conclusion.  —  Adults  with  congenital  heart  disease  are  considerably  more  likely  to  have  dif-
ﬁculty obtaining  a  mortgage  or  loan,  independent  of  their  congenital  heart  disease  severity.
Moreover,  despite  an  increased  obtainment  of  a  loan  in  patients  classiﬁed  as  ‘mild’,  the  refusal
rates were  identical  for  patients  classiﬁed  as  having  ‘signiﬁcant’  or  ‘complex’  congenital  heart
disease, although  their  prognosis  is  different.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Introduction.  —  Les  progrès  dans  la  prise  en  charge  des  enfants  atteints  d’une  cardiopathie
congénitale  ont  conduit  la  majorité  de  ces  patients  jusqu’à  l’âge  adulte.  Malgré  l’augmentation
de leur  espérance  de  vie,  peu  de  données  existent  sur  leur  qualité  de  vie,  en  particulier  sur
leur accès  à  l’assurance  d’un  prêt.
But. — Étudier  les  résultats  des  demandes  de  prêt  effectuées  par  des  patients  atteints  de
cardiopathie  congénitale  de  gravité  différente.
Méthode.  —  Quatre  cent  soixante-seize  patients  ont  été  contactés  pour  répondre  à  un  question-
naire concernant  leur  demande  de  prêt.  Parmi  eux,  142  ont  répondu.  Ces  patients  ont  été  classés
en trois  catégories  en  fonction  de  la  complexité  de  leur  cardiopathie  congénitale,  selon  la
conférence  de  Bethesda  (cardiopathie  congénitale  « minime  »,  « signiﬁcative  » et  « complexe  »).
Résultats. —  Parmi  les  patients  interrogés,  90  (64  %)  ont  effectué  une  demande  de  prêt,  17
(16,5 %)  n’ont  pas  déclaré  leur  cardiopathie  à  la  compagnie  d’assurance,  13  ont  eu  des  refus
d’assurance  et  39  des  tarifs  majorés.  Cela  concernait  surtout  les  groupes  de  patients  avec  des
cardiopathies  congénitales  « signiﬁcatives  » et  « complexes  » (p  <  0,0001  et  p  <  0,003,  respecti-
vement).  L’âge,  le  sexe,  la  notion  d’autres  maladies,  les  facteurs  de  risque  cardiovasculaires
et la  durée  de  l’emprunt  n’avaient  pas  d’inﬂuence  sur  les  résultats  des  demandes  de  prêt.
Conclusion.  —  Malgré  une  amélioration  de  l’accès  à  l’assurance  pour  les  patients  avec  une
cardiopathie  congénitale  simple,  le  taux  de  refus  reste  le  même  pour  les  patients  avec  une
cardiopathie  congénitale  de  complexité  intermédiaire  ou  sévère  bien  que  leur  pronostic  diffère.
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mprovement  in  the  diagnosis  and  management  of  children
ith  congenital  heart  disease  (CHD)  has  led  to  a  rapid
ncrease  in  the  population  of  adults  with  heart  defects.
hese  numbers  are  now  approaching  one  million  in  North
merica,  with  more  adults  (aged  >  16  years)  than  children
ith  CHD  [1].  A  similar  increase  has  occurred  in  Western
urope  [2].  While  lifespan  has  increased  markedly  for  these
atients,  little  is  known  about  their  ability  to  obtain  a
ortgage  or  consumer  loan.  Mortgage  application  is  often
 necessity  and  a  source  of  anxiety  for  most  individu-
ls;  and  this  anxiety  is  often  ampliﬁed  in  CHD  patients.
uestionnaire  studies  of  provider  companies  and  consen-
us  statements  suggest  that  most  adults  with  CHD  would  be
enied  insurance  or  subject  to  higher  rates  [3—6]. A  number
f  large-scale,  long-term  studies  are  available  for  evaluat-
ng  outcomes  in  many  cases  of  CHD.  This  has  facilitated  the
pproximation  of  mortality  risks  compared  with  a  healthy
ontrol  population,  which  in  turn  has  been  implemented
s  the  basis  of  policy  formulation  by  mortgage  insurance
ompanies.  However,  the  risk  rate  is  not  identical  for  all
nsurance  companies  and  the  heart  defect  prognosis  varies
ccording  to  the  lesion.  The  AERAS  convention  (s’Assurer
t  Emprunter  avec  un  Risque  Aggravé  de  Santé) [7]  aims
o  expand  access  of  loans  to  persons  who  have  or  have
ad  a  severe  disease.  This  consensus  was  signed  in  January
007  by  governments,  banking  trade  associations,  public  and
rivate  insurance  companies  and  associations  of  consumers
c
d
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ss  droits  réservés.
nd  patients.  Nevertheless,  the  loan  application  status  of
atients  with  CHD  in  France  remains  unknown.
To  determine  the  consumer  loan  and  mortgage  status  in
dults  with  CHD  within  France,  we  investigated  obtainment
f  a  mortgage  or  consumer  loan  in  a  cohort  of  CHD  patients.
e  were  particularly  interested  to  establish  whether  con-
enital  heart  lesions  have  a speciﬁc  effect  on  mortgage  and
oan  application  outcomes.
opulation and methods
rom  the  database  of  our  adult  CHD  unit,  476  patients  with
HD  were  selected  and  contacted  by  phone.  Patients  aged
ess  than  30  years  at  the  time  of  contact  were  excluded.
ndeed,  more  than  two-thirds  of  loan  applications  are  made
y  people  aged  more  than  35  years,  according  to  the  French
roperty  market  [8].  Patients  with  learning  difﬁculties,  lost
o  follow-up,  who  were  living  abroad,  deceased  or  with
earning  difﬁculties  were  also  excluded  from  further  study.
e  made  three  separate  attempts  to  reach  patients  by
hone  and  request  their  participation  in  our  study.  One  hun-
red  and  forty-two  patients  agreed  to  participate.
Patients  were  classiﬁed  according  to  the  Bethesda  clas-
iﬁcation,  which  takes  into  account  the  severity  and
omplexity  of  heart  disease.  The  CHD  population  was
ivided  into  ‘mild’,  ‘signiﬁcant’  and  ‘complex’  groups.
eart  lesions  were  grouped  as:  ‘mild’  when  they  were
imple  heart  diseases  with  good  outcome  (normal  or  near
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Table  1  Socioprofessional  categories  according  to  the
National  Institute  of  Statistics  and  Economic  Studies.
1  Farmers,  operators:  primary  sector
2  Artisans,  traders  and  entrepreneurs
3 Executives,  intellectual  professions
4 Intermediate  occupations
5  Blue-collar  employees
6  Workers
7  Retirees
Table  2  Comparison  of  loan  application  outcomes  in
adults  with  ‘mild’,  ‘signiﬁcant’  and  ‘complex’  congenital
heart  disease.
Classiﬁcation  Number  (%)
Standard
rates
Exclusions  and/or
extra  fees
Refusal
Mild  (n  =  8) 7 (87.5)  1 (12.5)  0
Signiﬁcant
(n  =  40)
5  (12.5)  26  (65.0)a 9  (22.5)a
Complex
(n  =  28)
6  (21.4)  18  (64.3)a 4  (14.3)a
a Refusal and insurance at non-standard rates were more fre-
quent in ‘signiﬁcant’ and ‘complex’ congenital heart disease
compared with ‘mild’ congenital heart disease (P < 0.0001 and
P = 0.003, respectively).
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b8  Other  people  without  work
normal  prognosis)  and  only  in  need  of  observation;  exam-
ples  of  these  are  mild  aortic  or  mitral  regurgitation,
mild  pulmonary  stenosis  and  repaired  atrial  or  ventricular
septal  defect.  CHDs  with  moderate  complexity  and  inter-
mediate  outcome,  where  correction  has  been  attempted
but  likely  requires  further  intervention,  were  classiﬁed  as
‘signiﬁcant’;  these  included  tetralogy  of  Fallot,  repaired
coarctation  and  repaired  complete  atrioventricular  septal
defect.  CHDs  with  greater  complexity  and  an  uncertain
or  poor  outcome,  such  as  Eisenmenger’s  syndrome,  cyan-
otic  congenital  heart,  Fontan  circulation,  single  ventricle
or  lesions  with  the  right  ventricle  supplying  the  systemic
circulation,  were  classiﬁed  as  ‘complex’.
Patients  were  further  classiﬁed  according  to  their  socio-
professional  category  deﬁned  by  INSEE  (National  Institute
of  Statistics  and  Economic  Studies;  Table  1).  Complications
related  to  their  heart  disease,  cardiovascular  risk  factors
and  other  co-morbidities  (such  as  cancer)  at  the  time  of
loan  application,  were  collected.  Finally,  we  asked  whether
the  patient  had  sought  advice  on  insurance  company  policies
from  a  patient  association.
Statistical analysis
All  values  were  expressed  as  mean  ±  standard  deviation
(SD).  Statistical  analyses  were  performed  using  Statview
V.5.0.1  software  (Adept  scientiﬁc,  Letchworth,  UK).  Differ-
ences  in  quantitative  variables  between  patient  groups  were
analysed  by  studying  the  variances.  The  Chi-square  test  was
used  to  compare  proportions.
Results
Among  the  142  patients  included  in  our  study,  63.4%  (n  =  90)
had  applied  for  loan  insurance;  13  had  submitted  two
loan  applications,  so  in  total  there  were  103  loan  appli-
cations.  Twenty-eight  percent  (n  =  14)  did  not  apply  for  a
loan  because  they  felt  that  their  condition,  particularly  in
cases  of  ‘signiﬁcant’  or  ‘complex’  CHD  (64%  and  36%,  respec-
tively),  would  impede  obtainment  of  the  loan.  Seventeen
patients  (16.5%)  obtained  insurance  without  disclosing  their
heart  disease  (Fig.  1);  only  79  of  the  patients  who  applied  for
a  loan  disclosed  their  heart  disease.  In  this  group,  the  mean
age  was  40.8  ±  9.6  years  (age  range  30—70  years).  Forty
patients  were  female.  Forty-seven  percent  (n  =  37)  were
executives  or  worked  in  intellectual  professions  (category
3),  24%  (n  =  19)  were  in  intermediate  occupations  (category
r
c
l
a)  and  15%  (n  =  12)  were  blue-collar  employees  (category
).  Most  of  the  patients  with  CHD  were  classiﬁed  as  having
signiﬁcant’  CHD  (54.4%,  n  =  43)  or  ‘complex’  CHD  (35.5%,
 =  28).  Socioprofessional  class  distribution  was  signiﬁcantly
ifferent  depending  on  the  severity  of  CHD:  patients  with
mild’  and  ‘signiﬁcant’  CHD  were  mainly  classed  in  cate-
ory  3  and  those  with  ‘complex’  CHD  were  mainly  classed  in
ategory  4.
Ninety  percent  (71/79)  of  loan  applications  were  for
ortgage  loans;  the  remainder  were  consumer  loans.  The
verage  loan  was  for  17  ±  5  years.  For  83.5%  of  patients
66/79),  the  insurance  application  outcome  was  positive
nd  18  patients  acquired  insurance  under  standard  rates.
orty-ﬁve  (57%)  loan  applications  were  obtained  either  by
xclusion  of  the  heart  defect  information  from  the  beneﬁts
olicy  or  with  increased  rates  (speciﬁcally,  32  were  obtained
t  increased  rates,  six  with  exclusion  and  seven  with  both).
he  refusal  rate  was  16.5%  (13/79).  Refusal  and  insurance
t  non-standard  rates  were  more  frequent  in  ‘signiﬁcant’
nd  ‘complex’  CHD  groups  (P  <  0.0001  and  P  =  0.003,  respec-
ively;  Table  2).  For  example,  75%  of  patients  with  tetralogy
f  Fallot  (n  =  9)  had  insurance  applications  accepted  with
mposed  increased  rates  or  by  exclusion  of  the  CHD  infor-
ation  from  the  policy;  one  patient  with  tetralogy  of  Fallot
as  refused  insurance.
Sex  and  age  had  no  inﬂuence  on  the  loan  application  out-
ome.  However,  insurability  was  signiﬁcantly  dependent  on
he  socioprofessional  class.  Rates  of  refusal  or  being  asked
o  pay  extra  were  signiﬁcantly  higher  in  categories  1,  4  and
 (P  =  0.01).  Twenty  patients  (25.3%)  had  cardiovascular  risk
actors  and  16  patients  (20.3%)  had  extracardiac  diseases
thyroid  disorders,  n  =  12;  asthma,  n  =  2;  breast  cancer,  n  =  2;
epatitis  B  virus  infection,  n  =  1;  hepatitis  C  virus  infec-
ion,  n  =  1)  at  the  time  of  application.  Cardiovascular  risk
actors  and  co-morbidities  did  not  inﬂuence  patient  insura-
ility.  Complications  related  to  CHD  did  not  change  the  loan
efusal  rate  nor  did  it  change  increased  rate  demands  or
ases  of  exclusion  of  CHD  information.  The  duration  of  the
oan  requested  (>  or  <  10  years,  P  =  0.22)  had  no  impact  on
pplication  request  outcome.
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Declarations  of  CHD  were  primarily  provided  by  question-
aire  (Table  3).  Decisions  on  loan  applications  were  made
y  contacting  the  supervising  cardiologist  for  eight  patients
ith  ‘signiﬁcant’  CHD  (20.0%)  and  four  patients  with  ‘com-
lex’  CHD  (14.2%).  Three  patients  (3.8%)  contacted  a  CHD
atient  association  for  advice  on  insurance  companies.
iscussionur  ﬁndings  indicate  that  patients  with  ‘signiﬁcant’  CHD
ave  the  same  increased  rate  of  refusal  of  insurance  at  stan-
ard  rates  as  those  with  ‘complex’  CHD.  Moreover,  patients
ith  simple  heart  lesions  are  more  likely  to  be  insured  at
a
b
t
Table  3  Comparison  of  types  of  medical  evaluation  required  b
heart  disease.
Number  (%)
Mild  (n  =  8)  
Medical  questionnaire  7  (87.5)  
GP  certiﬁcate  1  (12.5)  
Cardiologist  certiﬁcate  0  
GUCH  specialist  certiﬁcate  0  
GP: general practitioner; GUCH: grown-up congenital heart.s made two loan applications.
tandard  rates.  These  ﬁndings  indicate  that  insurance  com-
anies  have  a  better  knowledge  of  the  group  of  patients
ith  ‘mild’  CHD,  which  was  not  the  case  in  the  study  by
rossland  et  al.  in  2004  [5].  However  insurability  outcome
s  identical  in  patient  groups  demonstrating  ‘intermediate’
r  ‘signiﬁcant’  heart  defects,  suggesting  an  absence  of  thor-
ugh  knowledge  among  insurance  companies.
Prognosis  varies  within  individual  lesions,  particularly
n  ‘signiﬁcant’  CHD.  For  example,  patients  with  trans-
osition  of  the  great  arteries  who  had  arterial  switch
perations,  without  coronary  complication  and  pulmonary
rtery  stenosis,  have  a  long-term  prognosis  that  should  not
e  different  from  normal.  However,  comprehensive  data  for
hese  patients  are  lacking.  In  general,  positive  prognostic
y  insurers  between  the  three  classiﬁcations  of  congenital
Signiﬁcant  (n  =  40)  Complex  (n  =  28)
17  (42.5)  19  (67.9)
8  (20.0)  4  (14.2)
7  (17.5)  1  (3.7)
8  (20.0)  4  (14.2)
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markers  include  the  presence  of  biventricular  circulation
and  a  systemic  left  ventricle,  repair  at  early  age,  good  func-
tional  capacity  and  the  absence  of  major  or  progressive
haemodynamic  lesions.  Recent  advances  in  the  treatment
of  adult  patients  with  ‘signiﬁcant’  CHD  have  improved  the
prognosis  for  this  group  of  patients,  which  tends  to  reach
the  prognosis  for  normal  control  populations  [9].  Therefore,
it  is  exceedingly  important  that  physicians  emphasize  pos-
itive  diagnostic  factors,  and  the  presence  and  absence  of
negative  prognostic  factors,  in  their  letters  for  insurance
purposes.
It is  surprising  that  decisions  by  loan  companies  are  often
made  without  contacting  the  supervising  cardiologist  and
that  premiums  are  probably  based  on  a  diagnosis  rather
than  on  details  of  the  haemodynamic  status  of  an  individual
patient.  This  attitude  will  particularly  penalize  patients  with
‘signiﬁcant’  CHD.  Insurance  companies  tend  to  categorize
each  diagnosis  similarly,  although  there  are  some  inconsis-
tencies  between  companies.  Therefore,  patients  declined
insurance  or  offered  insurance  at  high  premiums  by  one  com-
pany  should  seek  another  company.  Another  possibility  is  to
seek  advice  from  a  CHD  patient  association;  only  3%  of  the
patients  contacted  had  done  so.  Patient  associations  may
be  able  to  provide  advice  about  insurance  companies  with  a
track  record  of  providing  coverage.  Moreover,  patients  may
receive  a  more  favourable  response  from  insurance  com-
panies  when  followed  in  a  specialized  adult  clinic  where
management  of  CHD  and  its  late  complications  are  routine.
Interestingly,  we  found  that  age  does  not  affect  insur-
ability.  As  mortality  in  the  general  population  predictably
increases  with  age,  whereas  mortality  associated  with
CHD  remains  the  same,  mortality  ratios  for  CHD  patients
inevitably  decrease  with  age.  CHD  patients  may  therefore
have  a  better  chance  of  obtaining  coverage  after  the  age
of  50  years  compared  with  others.  Cardiovascular  risk  fac-
tors  seem  to  weigh  less  in  the  insurer’s  decision  than  heart
disease  in  this  population.  Extracardiac  diseases  also  do  not
affect  insurability.  This  may  be  because,  in  our  study,  they
were  essentially  thyroid  disorders,  which  are  less  severe
than  heart  disease.
In  2009,  the  Fédération  franc¸aise  des  sociétés
d’assurance  reported  results  of  the  AERAS  convention
[10].  This  showed  that  a  signiﬁcant  percentage  of  insurance
applications  are  made  by  individuals  with  increased  health
risks  (92.8%);  of  these,  49%  had  an  additional  premium  for
life  coverage  and  43—51%  had  an  exclusion  of  their  disease
from  the  beneﬁts  policy  in  the  case  of  disability  claims.
Only  1%  of  applications  were  denied.  These  results  were
controversial  among  patients  and  consumer  associations,
in  particular  where  disability  is  not  adequately  covered.
This  is  conﬁrmed  by  the  refusal  rates  of  patients  with
‘signiﬁcant’  CHD  in  our  study.  Many  patients  (40%)  were  not
aware  of  this  convention  [11]  and  some  banks  and  insurers
are  reluctant  to  apply  the  convention.
There  are  several  limitations  to  our  study.  First,  many
patients  refused  to  answer  the  questionnaire  by  phone.  Per-
haps  inclusion  in  our  study  would  have  been  greater  if  it
had  been  conducted  in  outpatient  clinics.  Comparison  of
insurability  according  to  CHD  severity  would  have  been  more
relevant  if  standardization  had  been  carried  out  according
to  age,  loan  amount  requested  and  socioprofessional  class,
for  each  heart  defect.  Further,  there  was  an  inherent  bias379
n patient  recruitment  due  to  the  database  we  used,  which
riginates  from  a  specialized  centre  that  follows  mainly
complex’  CHD  cases.  This  explains  the  small  number  of
espondents  to  our  study  who  displayed  simple  heart  lesions.
t  would  be  also  interesting  to  compare  the  CHD  population
ith  a  control  population,  to  assess  the  insurability  of  these
atients  compared  with  a  larger  spectrum  of  controls.
onclusion
here  is  still  extensive  disparity  in  the  insurability  issues
acing  adults  with  CHD,  predominantly  those  exhibiting
complex’  lesions.  Despite  advances  in  medical  interven-
ions,  including  innovative  surgical  and  catheter  techniques
nd  improved  risk  stratiﬁcation,  the  overall  prognosis,  and
herefore  insurability,  has  not  been  improved  for  these
dults.  The  improvements  in  insurability  are  dependent  on
he  need  for  ongoing  studies  and  information  transfer  from
arge-scale  and  long-term  studies.  Indeed  the  dissemination
f  this  information,  in  conjunction  with  a  co-ordinated  effort
etween  different  centres  to  describe  outcomes  in  high-
nd  low-risk  cohorts  in  this  population  of  patients,  will  be
ndispensable  for  improving  loan  attainments  in  CHD  patient
opulations.
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